About Bio Blast Pharma
Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. It also focuses on diseases with severe and debilitating manifestations. The Company has several drug candidates in clinical or preclinical development targeting neuromuscular/central nervous system (CNS) and mitochondrial diseases. Its drug candidates include Trehalose IV Solution, BB-FA (Bioblast-Friedreich's ataxia) and BBrm-02. The Company's product candidate platforms include Protein Stabilizing Platform, Read-through Platform and Mitochondrial Protein Replacement Platform.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ORPN
- Previous Close: $1.22
- 50 Day Moving Average: $1.22
- 200 Day Moving Average: $1.46
- 52-Week Range: $16,391,000.00 - $0.92
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.43
- P/E Growth: 0.00
- Market Cap: $19.18M
- Outstanding Shares: 16,391,000
- Beta: 0.16
- Return on Equity: -52.90%
- Return on Assets: -46.88%
Companies Related to Bio Blast Pharma:
- Current Ratio: 6.67%
- Quick Ratio: 6.67%
What is Bio Blast Pharma's stock symbol?
Bio Blast Pharma trades on the NASDAQ under the ticker symbol "ORPN."
Where is Bio Blast Pharma's stock going? Where will Bio Blast Pharma's stock price be in 2017?
2 analysts have issued 12 month price targets for Bio Blast Pharma's stock. Their predictions range from $15.00 to $23.00. On average, they anticipate Bio Blast Pharma's stock price to reach $19.00 in the next twelve months.
When will Bio Blast Pharma announce their earnings?
Bio Blast Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.
Who owns Bio Blast Pharma stock?
Bio Blast Pharma's stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.73%).
Who bought Bio Blast Pharma stock? Who is buying Bio Blast Pharma stock?
Bio Blast Pharma's stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
How do I buy Bio Blast Pharma stock?
Shares of Bio Blast Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Bio Blast Pharma stock cost?
One share of Bio Blast Pharma stock can currently be purchased for approximately $1.17.